Amgen's Imdelltra plus Imfinzi cuts death risk 58% in first-line maintenance SCLC
- Amgen presented Phase 3 data at ESMO 2026 for Imdelltra plus AstraZeneca's Imfinzi in first-line maintenance small cell lung cancer.
- The combination reduced the risk of death by 58% versus Imfinzi alone, per Endpoints News.
- A September topline release had reported a statistically significant overall survival gain in the DeLLphi-305 study, which randomized 563 patients.
💡 Points
A 58% cut in death risk against Imfinzi alone, in a 563-patient trial, makes tarlatamab plus durvalumab a credible new first-line maintenance standard in SCLC, a setting with few advances. Pairing with AstraZeneca's PD-L1 incumbent also moves Imdelltra from later-line use toward earlier lines, where its commercial ceiling is far higher. Tolerability and the exact survival figures will decide how fast adoption follows.
#ESMO26: Amgen's Imdelltra regimen more than halves risk of death in Phase 3 lung cancer trial ↗